AGS-004

BIOLOGICAL5 trials

Sponsors

McGill University Health Centre/Research Institute of the McGill University Health Centre, Argos Therapeutics, Cynthia L Gay, MD, University of North Carolina, Chapel Hill

Conditions

Acquired Immunodeficiency SyndromeHIVHIV InfectionHIV InfectionsHIV SeropositivityHIV-1 Infection

Phase 1

A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.

CompletedNCT00381212

McGill University Health Centre/Research Institute of the McGill University Health CentreAcquired Immunodeficiency Syndrome, HIV Seropositivity

Start: 2006-09-30End: 2008-11-30Updated: 2009-01-29

A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004

CompletedNCT02042248

Cynthia L Gay, MDHIV

Start: 2014-03-31End: 2016-05-31Updated: 2017-05-04

Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

TerminatedNCT02707900

University of North Carolina, Chapel HillHIV-1 Infection

Start: 2016-03-31End: 2018-07-11Updated: 2019-10-07

Phase 2

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

CompletedNCT00672191

Argos TherapeuticsHIV Infections

Start: 2008-02-29End: 2011-11-30Updated: 2013-01-29

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

CompletedNCT01069809

Argos TherapeuticsHIV Infection

Start: 2010-07-31End: 2015-09-30Updated: 2017-01-24